These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 21862536)
1. Cost comparison of ranibizumab and bevacizumab. Jackson TL; Kirkpatrick L BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536 [No Abstract] [Full Text] [Related]
2. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds. Torjesen I BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948 [No Abstract] [Full Text] [Related]
3. A licence to cure. Aronson JK; Ferner RE BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026 [No Abstract] [Full Text] [Related]
5. Legal. PCTs taken to court over use of cheaper drug. Calkin S Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353 [No Abstract] [Full Text] [Related]
6. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740 [TBL] [Abstract][Full Text] [Related]
7. Why have UK doctors been deterred from prescribing Avastin? Cohen D BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024 [No Abstract] [Full Text] [Related]
8. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery. Harris MJ BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986 [No Abstract] [Full Text] [Related]
9. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin). Rhodes C; Harris J; Sulston J; Spanswick C J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806 [TBL] [Abstract][Full Text] [Related]
10. Attacks on publicly funded trials: what happens when industry does not want to know the answer. Cohen D BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025 [No Abstract] [Full Text] [Related]
11. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows. Hawkes N BMJ; 2012 May; 344():e3275. PubMed ID: 22573655 [No Abstract] [Full Text] [Related]
12. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration. Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511 [TBL] [Abstract][Full Text] [Related]
13. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? Lotery A; MacEwen C BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142 [No Abstract] [Full Text] [Related]
14. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice? Heier JS Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361 [No Abstract] [Full Text] [Related]
15. Avastin and Lucentis: a guide through the legal maze. Lock D BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023 [No Abstract] [Full Text] [Related]
16. Blanket disapproval of all unlicensed indications is wrong. Evans SJ BMJ; 2011 Nov; 343():d7726. PubMed ID: 22127456 [No Abstract] [Full Text] [Related]